Show simple item record

dc.contributor.authorEstambale, Benson B.
dc.date.accessioned2018-06-12T13:13:16Z
dc.date.available2018-06-12T13:13:16Z
dc.date.issued1995
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pubmed/7796767
dc.identifier.urihttp://ir.jooust.ac.ke:8080/xmlui/handle/123456789/1274
dc.description.abstractSafety, tolerance and immunogenicity of the purified Vi polysaccharide vaccine (Typhim Vi) against typhoid fever was evaluated in primary school children aged 5-15 years. A total of 435 children were vaccinated, each with a single intramuscular injection in the left deltoid muscle. One hundred and ten children were randomly selected for blood samples on day 0 (pre vaccination) and day 30 (post vaccination). Vi antibodies studied by Radio immuno assay (RIA) on 97(88%) paired sera showed a seroconversion rate of 76.2% and seroprotection rate after vaccination was 74.2%, while 6.2% of children already had protective immunity before vaccination. The vaccine was well tolerated. Most commonly reported reactions were mild pain at site of injection (83%), and a few complained of mild swelling (4.6%), induration (1.1%), itching (1.1%) and headaches (1.4%). All reactions were of mild severity and disappeared within 24 to 48 hours.en_US
dc.language.isoenen_US
dc.publisherPubMeden_US
dc.titleyphim Vi vaccine against typhoid fever: A clinical trial in Kenyaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record